Zai Lab/$ZLAB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Ticker
$ZLAB
Sector
Primary listing
Employees
1,869
Headquarters
Website
Zai Lab Metrics
BasicAdvanced
$2.4B
-
-$1.92
-
-
Price and volume
Market cap
$2.4B
52-week high
$44.34
52-week low
$21.52
Average daily volume
795K
Financial strength
Current ratio
2.871
Quick ratio
2.285
Long term debt to equity
1.426
Total debt to equity
28.866
Interest coverage (TTM)
-47.96%
Profitability
EBITDA (TTM)
-213.793
Gross margin (TTM)
49.48%
Net profit margin (TTM)
-46.83%
Operating margin (TTM)
-51.61%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-13.29%
Return on equity (TTM)
-28.97%
Valuation
Price to revenue (TTM)
5.334
Price to book
3.18
Price to tangible book (TTM)
3.44
Price to free cash flow (TTM)
-11.194
Free cash flow yield (TTM)
-8.93%
Free cash flow per share (TTM)
-1.956
Growth
Revenue change (TTM)
24.14%
Earnings per share change (TTM)
-30.76%
3-year revenue growth (CAGR)
30.96%
3-year earnings per share growth (CAGR)
-32.32%
What the Analysts think about Zai Lab
Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.
Bulls say / Bears say
ZL-1310 (DLL3 ADC) Phase 1a/1b data presented at ASCO 2025 showed a 67% objective response rate across all dose levels and 79% at 1.6 mg/kg, with a favorable safety profile indicating strong early efficacy potential (Business Wire).
The U.S. FDA granted Fast Track designation to ZL-1310 for treatment of extensive-stage small cell lung cancer in May 2025, underscoring regulatory support and potential for expedited development (Business Wire).
China’s National Medical Products Administration accepted the Biologics License Application for TIVDAK (tisotumab vedotin) in March 2025, paving the way for first-in-class ADC approval in recurrent metastatic cervical cancer and expanding Zai Lab’s commercial footprint in Greater China (RTTNews).
Despite 9% year-over-year revenue growth in Q2 2025, Zai Lab reported a net loss of $40.7 million, highlighting ongoing unprofitability and substantial cash burn before achieving projected profitability in Q4 2025 (Business Wire).
Sales of ZEJULA declined to $41.0 million in Q2 2025 from $45.0 million a year earlier, reflecting competitive pressure within the PARP inhibitor class and potential risk to key product revenue stability (Business Wire).
ZL-1310 remains in early-phase clinical development with registrational studies only slated to start in the second half of 2025 and potential FDA approval not expected until 2027, creating a lengthy timeline before material commercial revenue can be realized (Business Wire).
Data summarised monthly by Lightyear AI. Last updated on 7 Nov 2025.
Zai Lab Financial Performance
Revenues and expenses
Zai Lab Earnings Performance
Company profitability
Zai Lab News
AllArticlesVideos
Zai Lab Announces Participation in Investor Conferences in November and December 2025
Business Wire1 week ago
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
Business Wire2 weeks ago
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zai Lab stock?
Zai Lab (ZLAB) has a market cap of $2.4B as of November 09, 2025.
What is the P/E ratio for Zai Lab stock?
The price to earnings (P/E) ratio for Zai Lab (ZLAB) stock is 0 as of November 09, 2025.
Does Zai Lab stock pay dividends?
No, Zai Lab (ZLAB) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Zai Lab dividend payment date?
Zai Lab (ZLAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Zai Lab?
Zai Lab (ZLAB) does not currently have a Beta indicator.